[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334714-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334714-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","incidence-of-chemotherapy-related-cardiac-dysfunction-in-cancer-patients-meta-analysis","Incidence of chemotherapy-related cardiac dysfunction in cancer patients - meta-analysis","","Cancer patients face an increasing burden of chemotherapy-related cardiac dysfunction, yet incidence estimates vary widely across individual studies. This meta-analysis searched PubMed and EMBASE from inception to May 1, 2023, including studies that reported incidence in cancer patients. Fifty-three studies with 35,651 participants were pooled to estimate an overall incidence of 63.21 per 1,000 person-years (95% CI: 57.28–69.14). Incidence rose rapidly within 6 months, then appeared to plateau over longer follow-up, with higher rates in patients aged ≥50 years and in specific cancer types.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/incidence-of-chemotherapy-related-cardiac-dysfunction-in-cancer-patients-meta-analysis/334714/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/incidence-of-chemotherapy-related-cardiac-dysfunction-in-cancer-patients-meta-analysis/334714.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of this study?","Question",{"text":63,"@type":64},"To estimate the overall incidence of chemotherapy-related cardiac dysfunction in cancer patients using a meta-analysis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the incidence estimate calculated?",{"text":68,"@type":64},"The analysis pooled results from 53 studies (35,651 individuals) identified through searches in PubMed and EMBASE up to May 1, 2023.",{"name":70,"@type":61,"acceptedAnswer":71},"What timing pattern was observed after starting chemotherapy?",{"text":72,"@type":64},"Incidence increased steeply within the first 6 months of cancer chemotherapy, then appeared to plateau with longer follow-up.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334714,1790147770,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","DOI: 10.1002/clc.24269  \nCLINICA L ARTI CLE  \nIncidence of chemotherapy‐related cardiac dysfunction in cancer patients  \nHai‐Wei Deng MD1,2  | Rui Fan MD2,3 | Yuan‐Sheng Zhai MD1,2 | Jie Li MD2,3 | Zhi‐Bin Huang MD, PhD1,2 | Long‐Yun Peng MD, PhD1,2  \n1Department of Cardiology, The First Affiliated Hospital, Sun Yat‐Sen University, Guangzhou, China  \n2Key Laboratory on Assisted Circulation Ministry of Health, Guangzhou, China 3Department of Medical Ultrasonics, The First Affiliated Hospital, Sun Yat‐Sen University, Guangzhou, China  \nCorrespondence  \nZhi‐Bin Huang, MD, PhD and Long‐Yun Peng, MD, PhD, Department of Cardiology, The First Affiliated Hospital, Sun Yat‐Sen University, 58 Zhongshan Rd \\#2, Guangzhou, Guandong 510080, China.  \nEmail: [hzbin2603@163.com](hzbin2603@163.com) and [penglyun@mail.sysu.edu.cn](penglyun@mail.sysu.edu.cn)  \nFunding information  \nMedical Science and Technology Research Foundation of Guangdong Province,  \nGrant/Award Number: Project ref A2022050; The Guangdong Natural Science Foundation, Grant/Award Number: 2015A030313011  \nAbstract  \nBackground: Cancer patients are increasingly affected by chemotherapy‐related cardiac dysfunction. The reported incidence of this condition vary significantly across different studies.  \nHypothesis: A better comprehensive understanding of chemotherapy‐related cardiac dysfunction incidence in cancer patients is imperative. Therefore, we performed a meta‐analysis to establish the overall incidence of chemotherapy‐ related cardiac dysfunction in cancer patients.  \nMethods: We searched articles in PubMed and EMBASE from database inception to May 1, 2023 . Studies that reported the incidence of chemotherapy‐related cardiac dysfunction in cancer patients were included.  \nResults: A total of 53 studies involving 35 651 individuals were finally included in the meta‐analysis. The overall pooled incidence of chemotherapy‐related cardiac dysfunction in cancer patients was 63.21 per 1000 person‐years (95% CI: 57.28−69 . 14) . The chemotherapy‐related cardiac dysfunction incidence increased steeply within half a year of cancer chemotherapy. Also, the trend of chemotherapy‐ related cardiac dysfunction incidence appeared to have plateaued after a longer duration of follow‐up. In addition, chemotherapy‐related cardiac dysfunction incidence rates are significantly higher among patients with age ≥50 years versus patients with age \u003C50 years (99 .96 vs. 34.48 per 1000 person‐years) . The incidence rate of cardiac dysfunction was higher among breast cancer patients (72.97 per 1000 person‐years), leukemia patients (65.21 per 1000 person‐years), and lymphoma patients (55 .43 per 1000 person‐years) .  \nConclusion: Our meta‐analysis unveiled a definitive overall incidence rate of chemotherapy‐related cardiac dysfunction in cancer patients. In addition, it was found that the risk of developing this condition escalates within the initial 6 months  \n\n| Abbreviations: CI, confidence Interval; LVEF, left ventricular ejection fraction; RCT, random controlled trial; ROS, reactive oxygen species. Hai‐Wei Deng, Rui Fan, and Yuan‐Sheng Zhai contributed equally to this study. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC. |\n\nClin Cardiol. 2024;47:e24269 .  \n[https://doi.org/10.1002/clc.24269](https://doi.org/10.1002/clc.24269)  \n[wileyonlinelibrary.com/journal/clc](wileyonlinelibrary.com/journal/clc)  \n1 of 8  \npostchemotherapy, subsequently tapering off to become statistically insignificant after a duration of 6 years.  \nKEYWO R DS  \ncancer, cardiac dysfunction, chemotherapy  \n1 | INTRODUCTION  \nCancer significantly contributes to the global burden of disease and is among the leading etiologies of death.1 The deployment of anticancer drugs has become incre","cbCairHBYGxcMqT8","https://ap.wps.com/l/cbCairHBYGxcMqT8","pdf",1462801,"English","# Introduction\n## Background and rationale\n# Methods\n## Literature search and study selection\n# Results\n## Pooled incidence and subgroup patterns\n# Conclusion\n## Overall incidence and time-course insight","[{\"question\":\"What is the main objective of this study?\",\"answer\":\"To estimate the overall incidence of chemotherapy-related cardiac dysfunction in cancer patients using a meta-analysis.\"},{\"question\":\"How was the incidence estimate calculated?\",\"answer\":\"The analysis pooled results from 53 studies (35,651 individuals) identified through searches in PubMed and EMBASE up to May 1, 2023.\"},{\"question\":\"What timing pattern was observed after starting chemotherapy?\",\"answer\":\"Incidence increased steeply within the first 6 months of cancer chemotherapy, then appeared to plateau with longer follow-up.\"}]","Incidence of chemotherapy-related cardiac dysfunction in cancer patients - meta-analysis | PDF",1790007982]